APONTIS PHARMA Reports Revenue Growth in 9M 2024 Amid Revised Forecast

APONTIS PHARMA AG, a German pharmaceutical company, announced a notable increase in revenue from their Single Pill combinations for the first nine months of 2024, totaling EUR 26.2 million compared to EUR 17.9 million in the previous year. This growth is partly attributed to a EUR 5.6 million contribution from their collaboration with Novartis on asthma products.

The company's EBITDA improved significantly to EUR 2.7 million, marking a substantial turnaround from the EUR -7.0 million loss reported in 9M 2023. However, delays in the revised marketing concept led to a slight reduction in the full-year 2024 revenue forecast, now expected to reach EUR 48.7 million.

APONTIS PHARMA also faced a decline in net liquidity from EUR 20.8 million to EUR 14.3 million by the end of September 2024. Nevertheless, the company's equity ratio stands at a solid 68.4%, showcasing its financial resilience.

The executive team, led by CEO Bruno Wohlschlegel, remains optimistic about the ongoing growth trajectory and the gradual impact of the revised marketing strategy, despite the revised revenue expectations.